- Sept 8, 2021: Biomarkers
- Sept 22, 2021: Neuroscience and Epidemiology of Drug Addiction
- Oct 6, 2021: Genetics
- Oct 20, 2021: Zebrafish - Development
- Nov 10, 2021: Sensor & Apps for Health Monitoring
- Dec 8, 2021: Development of Chemotherapeutics
- Jan 5, 2022: Kentucky Commercialization Ventures
- Jan 19, 2022: Neurotoxicity & Brain Health
- Feb 9, 2022: Bacteria and Enzymes
- Feb 23, 2022: Biotechnology
- March 9, 2022: Psychology & Language
- March 23, 2022: Genomics and Electron Microscopy Cores
- April 6, 2022: R16 Funding Mechanism
Dec 8, 2021: Development of Chemotherapeutics
-
4 pm: Blairanne Williams, Western Kentucky University Chemistry, The regulation of biological activity by platinum leaving ligands in cellular models of cancer
-
4:15 pm: Ali Er, Western Kentucky University Physics and Astronomy, Methylene blue functionalized silver nanoparticles: A potential photodynamic therapy agent for treatment of prosthetic joint infection
-
4:30 pm: Daniel Scott, Centre College Chemistry, Developing Novel Anti-Cancer Mithramycin Formulations and Nanoparticle Delivery System Design
-
4:45 pm: Lindsey Cormier, Eastern Kentucky University Biology and Chemistry, Platinum-LHRH, a newly synthesized targeting chemotherapeutic agent directed towards breast cancer
- Sept 8, 2021: Biomarkers
- Sept 22, 2021: Neuroscience and Epidemiology of Drug Addiction
- Oct 6, 2021: Genetics
- Oct 20, 2021: Zebrafish - Development
- Nov 10, 2021: Sensor & Apps for Health Monitoring
- Dec 8, 2021: Development of Chemotherapeutics
- Jan 5, 2022: Kentucky Commercialization Ventures
- Jan 19, 2022: Neurotoxicity & Brain Health
- Feb 9, 2022: Bacteria and Enzymes
- Feb 23, 2022: Biotechnology
- March 9, 2022: Psychology & Language
- March 23, 2022: Genomics and Electron Microscopy Cores
- April 6, 2022: R16 Funding Mechanism